市場調查報告書
商品編碼
1096558
尼古丁替代療法的全球市場:現狀分析與預測(2021年~2027年)Nicotine Replacement Therapy Market: Current Analysis and Forecast (2021-2027) |
全球尼古丁替代療法的市場規模在預測期間(2021年~2027年)中預計將以約14%的年複合成長率成長。
政府啟發計劃的增加、呼吸系統疾病等慢性病增加,以及越來越多的年輕人沉迷於吸煙和煙草消費,這些都預計將推動尼古丁替代療法市場的增長。
本報告提供全球尼古丁替代療法市場的相關調查,提供市場洞察,市場趨勢,競爭模式,企業概要等全面性資訊。
The nicotine replacement therapy is expected to witness a CAGR of around 14% during the forecast period (2021-2027). Nicotine replacement therapy (NRT) is effective in helping people quit smoking through patches, inhalers, gums, sprays, and lozenges that are free of the toxic compounds found in tobacco. Factors that are accelerating its market growth such as growing awareness programs by the government, rising chronic diseases such as respiratory diseases, and cardiovascular diseases coupled with the increasing young population addicting to smoking or tobacco consumption are accentuating the market size of nicotine replacement therapy. In addition, technological advancements in the NRT market are continuing, resulting in an increase in the number of people moving to advanced products. The acceptance of NRT is anticipated to be aided by new innovations such as heat-not-burn products, flavored chewing gums, and lozenges are propelling the market growth.
Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, AstraZeneca, Johnson & Johnson Private Limited, Merck & Co. Inc., and Cipla Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new and advanced nicotine replacement therapy.
Based on type, the nicotine replacement therapy market is segmented into gums, patches, lozenges, inhalers, and others. In 2020, The gums category is anticipated to witness a significant growth rate over the forecast period owing to the rising prevalence of chronic diseases, increasing awareness of smoking & tobacco consumption, and the introduction of technologically advanced products are the factors driving the demand for nicotine replacement therapy. Therefore, increasing awareness worldwide is anticipated to increase the NRT product's sales during the forecast period. Furthermore, The World Health Organization (WHO) Framework Convention on Tobacco Control (WHO FCTC) is the first international public health treaty negotiated under WHO auspices. This treaty contains guidelines and requirements for the implementation of the most cost-effective tobacco control measures available necessary for reducing the smoking epidemic.
Based on distribution channel, the nicotine replacement therapy market is categorized into online pharmacies and offline pharmacies. In 2020, the offline category dominated the market. This is mainly due to the increased number of patients who are suffering from chronic diseases such as cancer, respiratory disease, and excessive smoking habits. For instance, according to the Centers for Disease Control and Prevention (CDC), People who smoke cigarettes are 15 to 30 times more likely to get lung cancer or die from lung cancer than people who do not smoke. These factors will increase sales of NRT products & spread awareness about the importance of prohibiting smoking. In addition, online pharmacies are projected to witness the fastest growth during the forecast period. Furthermore, the flexibility, comfort, and convenience provided by the online purchase of medications are major factors driving the segment.
For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Australia, Rest of Asia-Pacific) and Rest of World. In 2020, North America accounted for a significant market share. This is mainly due to the rising adoption rate of NRT products, heated tobacco, and well-established healthcare infrastructure are some key factors that will drive the market growth rate in this region. Furthermore, to reduce smoking & tobacco consumption the U.S. Food and Drug Administration (FDA) approved nicotine replacement therapy by introducing products such as nicotine gums, patches, lozenges, and others. pharmaceutical companies GlaxoSmithKline and Johnson & Johnson have been supplying products worldwide.
The nicotine replacement therapy market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.